Opus Genetics (IRD) Return on Sales (2010 - 2026)

Opus Genetics (IRD) has 9 years of Return on Sales data on file, last reported at 0.3% in Q1 2026.

• Quarterly Return on Sales fell 29.0% year-over-year to 0.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.09% (down 5.0% YoY) and the FY2025 annual result came in at 0.03%, up 2.0% from the prior year.
• Return on Sales retreated to 0.3% in Q1 2026 per IRD's latest filing, from 0.04% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q4 2022 and bottomed at 0.45% in Q2 2022.
• The 5-year median for Return on Sales is 0.04% (2024), against an average of 0.1%.
• The widest annual swing landed in 2022, when Return on Sales surged 97 bps; it then slipped 29 bps in 2026.
• Tracing IRD's Return on Sales over 5 years: stood at 0.01% in 2022, then slumped by 433 bps to 0.03% in 2023, then sank by 188 bps to 0.08% in 2024, then surged by 48 bps to 0.04% in 2025, then tumbled by 611 bps to 0.3% in 2026.
• Per Business Quant, the three latest IRD Return on Sales figures stand at 0.3% (Q1 2026), 0.04% (Q4 2025), and 0.06% (Q3 2025).

Peer Comparison